Global Central Nervous System Partnering 2010-2017: Deal trends, players and financials

Publisher Name :
Date: 01-Nov-2017
No. of pages: 600
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

Global Central Nervous System Partnering 2010 to 2017 provides the full collection of Central Nervous System disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Central Nervous System partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Central Nervous System partnering agreement structure

Central Nervous System partnering contract documents

Top Central Nervous System deals by value

Most active Central Nervous System dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.

The report presents financial deal terms values for Central Nervous System deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Central Nervous System dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Central Nervous System dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Central Nervous System deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Central Nervous System dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Central Nervous System deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Central Nervous System partnering deals by specific Central Nervous System target announced since 2010. The chapter is organized by specific Central Nervous System therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Central Nervous System partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Central Nervous System partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Central Nervous System technologies and products.

Report scope

Global Central Nervous System Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Central Nervous System trends and structure of deals entered into by leading companies worldwide.

Global Central Nervous System Partnering 2010 to 2017 includes:

Trends in Central Nervous System dealmaking in the biopharma industry since 2010

Analysis of Central Nervous System deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Central Nervous System deal contract documents

Comprehensive access to over 3500 Central Nervous System deal records

The leading Central Nervous System deals by value since 2010

Most active Central Nervous System dealmakers since 2010

The report includes deals for the following indications: Cerebral palsy, Creutzfeldt Jakob disease, Dizziness, Epilepsy, Faints, Falls, Guillain Barre syndrome, Headache, Meningitis (Bacterial, Meningococcal, Pneumococcal), Mycobacterium tuberculosis (TB), Haemophilus influenzae Type B (Hib), Migraine, Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig's Disease, Multiple sclerosis, Nausea, Neuropathy, Pain, Neuralgia, Fibromyalgia, Paralysis, Parkinson's disease, Restless leg syndrome, Spinal cord, Stroke, Stuttering, Traumatic Brain Injury, Vertigo, Weakness, plus other CNS indications.

In Global Central Nervous System Partnering 2010 to 2017, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Central Nervous System Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 1,500 central nervous system deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are the sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Key benefits

Global Central Nervous System Partnering 2010 to 2017 provides the reader with the following key benefits:

In-depth understanding of Central Nervous System deal trends since 2010

Access Central Nervous System deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Central Nervous System partner companies

Comprehensive access to over 750 links to actual Central Nervous System deals entered into by the world's biopharma companies

Indepth review of Central Nervous System deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Central Nervous System opportunities

Uncover companies actively partnering Central Nervous System opportunities

Global Central Nervous System Partnering 2010-2017: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Central Nervous System dealmaking
2.1. Introduction
2.2. Central Nervous System partnering over the years
2.3. Central Nervous System partnering by deal type
2.4. Central Nervous System partnering by industry sector
2.5. Central Nervous System partnering by stage of development
2.6. Central Nervous System partnering by technology type
2.7. Central Nervous System partnering by therapeutic indication

Chapter 3 -Financial deal terms for Central Nervous System partnering
3.1. Introduction
3.2. Disclosed financials terms for Central Nervous System partnering
3.3. Central Nervous System partnering headline values
3.4. Central Nervous System deal upfront payments
3.5. Central Nervous System deal milestone payments
3.6. Central Nervous System royalty rates

Chapter 4 - Leading Central Nervous System deals and dealmakers
4.1. Introduction
4.2. Most active in Central Nervous System partnering
4.3. List of most active dealmakers in Central Nervous System
4.4. Top Central Nervous System deals by value

Chapter 5 - Central Nervous System contract document directory
5.1. Introduction
5.2. Central Nervous System partnering deals where contract document available

Chapter 6 - Central Nervous System dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Central Nervous System therapeutic target

Appendices

Appendix 1 - Directory of Central Nervous System deals by company A-Z 2010 to 2017
Appendix 2 - Directory of Central Nervous System deals by deal type 2010 to 2017
Appendix 3 - Directory of Central Nervous System deals by stage of development 2010 to 2017
Appendix 4 - Directory of Central Nervous System deals by technology type 2010 to 2017
Further reading on dealmaking
Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

List of Figures

Figure 1: Central Nervous System partnering since 2010
Figure 2: Central Nervous System partnering by deal type since 2010
Figure 3: Central Nervous System partnering by industry sector since 2010
Figure 4: Central Nervous System partnering by stage of development since 2010
Figure 5: Central Nervous System partnering by technology type since 2010
Figure 6: Central Nervous System partnering by indication since 2010
Figure 7: Central Nervous System deals with a headline value
Figure 8: Central Nervous System deals with upfront payment values
Figure 9: Central Nervous System deals with milestone payment
Figure 10: Central Nervous System deals with royalty rates
Figure 11: Active Central Nervous System dealmaking activity- 2010 to 2017
Figure 12: Top Central Nervous System deals by value since 2010
  • Global Implant Abutments Detailed Analysis Report 2018-2023
    Published: 12-Jan-2018        Price: US 4250 Onwards        Pages: 121
    This report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in Implant Abutments industry. This report splits Implant Abutments market by Implant Abutment Shape, by Materials, by Connections, which covers the history data information from 2013 to 2017 and forecast from 2018 to 2023. This report fo......
  • Global Implant Abutments Market Research Report 2018-2023 by Players, Regions, Product Types & Applications
    Published: 12-Jan-2018        Price: US 3380 Onwards        Pages: 122
    The global Implant Abutments market is valued at XX million USD in 2017 and is expected to reach XX million USD by the end of 2023, growing at a CAGR of XX% between 2017 and 2023. This report offers an overview of the market trends, drivers, and barriers with respect to the Implant Abutments market. It also provides a detailed overview of the market of different regions across United States, Europe, China, Japan, India, Southeast Asia and Others. The report categorizes Implant Abu......
  • EMEA (Europe, Middle East and Africa) Dental Drug Market 2017 Forecast to 2022
    Published: 12-Jan-2018        Price: US 4480 Onwards        Pages: 121
    There are a number of different drugs that dentist may prescribe, depending on patient's condition. Some medications are prescribed to fight certain oral diseases, to prevent or treat infections, or to control pain and relieve anxiety. The dose of the drugs and instructions on how to take them will differ from patient to patient, depending on what the drug is being used for, patient's age, weight, and other considerations. Scope of the Report: This report focuses on the Den......
  • Global Implant Abutment Sales Market Report 2017
    Published: 29-Dec-2017        Price: US 4000 Onwards        Pages: 116
    In this report, the global Implant Abutment market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Implant Abutment for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan......
  • Dental Pain - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 34
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dental Pain - Pipeline Review, H2 2017, provides an overview of the Dental Pain (Central Nervous System) pipeline landscape. A pain in the tooth is called dental pain. This can be caused by tooth decay, damaged filling, tooth fracture, etc. Symptoms of a toothache may include: tooth pain that may be sharp, throbbing, or constant. In some people, pain results only when pressure is applied to the too......
  • 2017 Top 5 Dental Drug Players in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 28-Dec-2017        Price: US 4960 Onwards        Pages: 126
    "This report will be delivered in 2-3 business days after the order is placed." The Global Dental Drug market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) of XX% from between 2016 and 2022. This report studies the global Dental Drug market, especially in North America, Europe, Asia-Pacific, South America, Middle East and Africa, focuses on the top 5 Dental Drug players in each re......
  • 2017-2022 Asia-Pacific Top Countries Dental Drug Market Report
    Published: 28-Dec-2017        Price: US 4660 Onwards        Pages: 126
    "This report will be delivered in 2-3 business days after the order is placed." In 2016, the Asia-Pacific Dental Drug market size was xx million USD and it will reach xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. This report studies Dental Drug in Asia-Pacific market, especially in China, Japan, Korea, Taiwan, India, Australia, Indonesia, Thailand and Philippines, focuses on the top players in each country, covering - Merc......
  • 2017-2022 China Dental Drug Market Report (Status and Outlook)
    Published: 28-Dec-2017        Price: US 3360 Onwards        Pages: 126
    "This report will be delivered in 2-3 business days after the order is placed." In 2016, the Dental Drug market size was xx million USD in China, and it will be xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. In China market, the top players include - Merck - Bayer - J&J - GSK - 3M - Sunstar - Colgate-Palmolive - DenMat - Showa Yakuhin Kako - Valeant Pharmaceuticals......
  • 2017-2022 Europe Top Countries Dental Drug Market Report
    Published: 28-Dec-2017        Price: US 4660 Onwards        Pages: 126
    "This report will be delivered in 2-3 business days after the order is placed." In 2016, the Europe Dental Drug market size was xx million USD and it will reach xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. This report studies Dental Drug in Europe market, especially in Germany, UK, France, Italy, Russia, Benelux, Turkey and other countries in Europe, focuses on the top players in each country, covering - Merck - Ba......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs